Announcements Trials
Browse Landscape

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 48Thoracic 37Lymphoid 8Other hematologic neoplasm 6Gynecologic 6Sarcoma 5Head & Neck 4Genitourinary 4CNS 4Dermatologic 3Breast 3Plasma cell 1Other solid neoplasm 1NET 1Myeloid 1Endocrine 1Classical hematology 1

Conditions

Neuroendocrine Tumors 531Multiple Endocrine Neoplasia Type 1 187Pituitary Neoplasms 186Thyroid Cancer, Papillary 178Pheochromocytoma 152Carcinoma, Neuroendocrine 140Thyroid Neoplasms 130Neoplasms 107Carcinoid Tumor 99Paraganglioma 98Adrenocortical Carcinoma 92Thyroid Carcinoma, Anaplastic 82Pancreatic Neoplasms 69Neoplasm Metastasis 67Insulinoma 61Adrenal Gland Neoplasms 61Gastro-enteropancreatic neuroendocrine tumor 58Carcinoma, Medullary 58Adenocarcinoma, Follicular 58Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 56Adenoma, Islet Cell 56Lung Neoplasms 50Sarcoma 49Colorectal Neoplasms 49Carcinoma, Renal Cell 49Melanoma 47Small Cell Lung Carcinoma 45Prostatic Neoplasms 44Head and Neck Neoplasms 43

Interventions

telotristat ethyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cachexia × Endocrine × Clear all
NCT04034745 2020-12-30

Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain

Cedars-Sinai Medical Center

Withdrawn
EndocrineGastrointestinalNET

Cachexia, Neoplasms, Pancreatic Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡